| Popis: |
Background The purpose of this study was to study the relationship between ALK&ROS1 gene rearrangement, EGFR mutation, non-ALK&ROS1/EGFR and their clinical characteristics in non-small cell lung cancer (NSCLC) patients to distinguish these different types. Methods Both ALK&ROS1 gene rearrangements and EGFR mutations testing were performed in 461 NSCLC patients. The clinical characteristics and associated pulmonary abnormalities were investigated. Results Of the 461 patients studied, we identified 175 cases with EGFR mutations (38.0%, 175/461). ALK gene fusions were identified in 33 cases (33/461, 7.2%) and ROS1 gene fusions were identified in 9 cases (9/461, 1.9%). In the EGFR-positive group, the majority were female (50.9%, P P P ALK&ROS1/EGFR group, the significant differences in ALK&ROS1-positive group were: younger (P P P = 0.001), adenocarcinoma (90.5%, P = 0.002) patients, appeared lymphangitic was more (23.8%, P = 0.044) and emphysema was less (9.5%, P EGFR mutation and ALK&ROS1 gene rearrangement were more likely to occur in young, non-smoking women. Patients with ALK&ROS1 gene rearrangements and EGFR mutations were less likely to develop emphysema. |
